Log In
Print
BCIQ
Print
Print this Print this
 

Squalamine eye drops (OHR-102)

  Manage Alerts
Collapse Summary General Information
Company Ohr Pharmaceutical Inc.
DescriptionTopical eye drop formulation of the synthetic small molecule anti-angiogenic aminosterol
Molecular Target Calmodulin
Mechanism of ActionAngiogenesis inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

U.S. - Fast Track (Treat wet age-related macular degeneration (AMD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today